<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="cfr.xsl"?>
<CFRGRANULE xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="CFRMergedXML.xsd">
  <FDSYS>
    <CFRTITLE>21</CFRTITLE>
    <CFRTITLETEXT>Food and Drugs</CFRTITLETEXT>
    <VOL>1</VOL>
    <DATE>2000-04-01</DATE>
    <ORIGINALDATE>2000-04-01</ORIGINALDATE>
    <COVERONLY>false</COVERONLY>
    <TITLE>Authority relating to determination of product primary jurisdiction.</TITLE>
    <GRANULENUM>5.32</GRANULENUM>
    <HEADING>Section 5.32</HEADING>
    <ANCESTORS>
      <PARENT HEADING="Title 21" SEQ="4">Food and Drugs</PARENT>
      <PARENT HEADING="CHAPTER I" SEQ="3">FOOD AND DRUG ADMINISTRATION,DEPARTMENT OF HEALTH ANDHUMAN SERVICES</PARENT>
      <PARENT HEADING="SUBCHAPTER A" SEQ="2">GENERAL</PARENT>
      <PARENT HEADING="PART 5" SEQ="1">DELEGATIONS OF AUTHORITY AND ORGANIZATION</PARENT>
      <PARENT HEADING="Subpart B" SEQ="0">Redelegations of Authority from the Commissioner of Food and Drugs</PARENT>
    </ANCESTORS>
  </FDSYS>
  <SECTION>
    <PRTPAGE P="42"/>
    <SECTNO>§ 5.32</SECTNO>
    <SUBJECT>Authority relating to determination of product primary jurisdiction.</SUBJECT>
    <P>The FDA ombudsman as product jurisdiction officer is authorized to determine whether the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), or the Center for Drug Evaluation and Research (CDER) has primary responsibility for premarket review and regulation of a product that constitutes a combination of a drug, device, or biological product under section 503(g)(1) of the Federal Food, Drug, and Cosmetic Act or that is a drug, device or biologic product where the center with primary jurisdiction is unclear or in dispute.</P>
    <CITA>[56 FR 58758, Nov. 21, 1991]</CITA>
  </SECTION>
</CFRGRANULE>
